99 related articles for article (PubMed ID: 16379155)
1. [The basic and clinical studies of moxifloxacin: the profile as respiratory quinolones].
Kohno S
Jpn J Antibiot; 2005 Oct; 58(5):431-44. PubMed ID: 16379155
[No Abstract] [Full Text] [Related]
2. Vancomycin, ceftazidime, and moxifloxacin can be safely stored in single-use, polypropylene syringes.
Armstrong BK; Mehta S; Kim SJ
Retina; 2011 Nov; 31(10):2134-6. PubMed ID: 22027802
[No Abstract] [Full Text] [Related]
3. A double mutation in the gyrA gene is necessary to produce high levels of resistance to moxifloxacin in Campylobacter spp. clinical isolates.
Ruiz J; Moreno A; Jimenez de Anta MT; Vila J
Int J Antimicrob Agents; 2005 Jun; 25(6):542-5. PubMed ID: 15876526
[TBL] [Abstract][Full Text] [Related]
4. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Wenzler S; Schmidt-Eisenlohr E; Daschner F
Chemotherapy; 2004 Apr; 50(1):40-2. PubMed ID: 15084805
[TBL] [Abstract][Full Text] [Related]
5. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
6. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.
Schmid DA; Depta JP; Pichler WJ
Clin Exp Allergy; 2006 Jan; 36(1):59-69. PubMed ID: 16393267
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
Sano C; Tatano Y; Shimizu T; Yamabe S; Sato K; Tomioka H
Int J Antimicrob Agents; 2011 Apr; 37(4):296-301. PubMed ID: 21353489
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
Galles AC; Jones RN; Sader HS
J Chemother; 2008 Feb; 20(1):38-42. PubMed ID: 18343741
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Sulochana S; Rahman F; Paramasivan CN
J Chemother; 2005 Apr; 17(2):169-73. PubMed ID: 15920901
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
Malik M; Drlica K
Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782
[TBL] [Abstract][Full Text] [Related]
11. parE mutations in Streptococcus pneumoniae may reduce bactericidal activity of respiratory fluoroquinolones.
Sun HK; Du X; DeRyke CA; Doern GV; Nicolau DP
Int J Antimicrob Agents; 2007 Feb; 29(2):230-2. PubMed ID: 17204405
[No Abstract] [Full Text] [Related]
12. In vitro activity of moxifloxacin against community respiratory pathogens in Qatar.
Elshafie SS; Al-Kuwari J
Int J Antimicrob Agents; 2004 Sep; 24(3):309-10. PubMed ID: 15325441
[No Abstract] [Full Text] [Related]
13. In vitro development of resistance to DX-619 and other quinolones in enterococci.
Wickman PA; Black JA; Smith Moland E; Thomson KS; Hanson ND
J Antimicrob Chemother; 2006 Dec; 58(6):1268-73. PubMed ID: 17062613
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Seral C; Barcia-Macay M; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
[TBL] [Abstract][Full Text] [Related]
15. Serine-to-asparagine substitution in the GyrA gene leads to quinolone resistance in moxifloxacin-exposed Chlamydia pneumoniae.
Rupp J; Gebert A; Solbach W; Maass M
Antimicrob Agents Chemother; 2005 Jan; 49(1):406-7. PubMed ID: 15616321
[TBL] [Abstract][Full Text] [Related]
16. Place of newer quinolones and rifampicin in the treatment of Gram-positive bone and joint infections.
Frippiat F; Meunier F; Derue G
J Antimicrob Chemother; 2004 Dec; 54(6):1158; author reply 1159. PubMed ID: 15498877
[No Abstract] [Full Text] [Related]
17. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Saravolatz LD; Leggett J
Clin Infect Dis; 2003 Nov; 37(9):1210-5. PubMed ID: 14557966
[TBL] [Abstract][Full Text] [Related]
18. Elevated levels of intestinal inflammation in Clostridium difficile infection associated with fluoroquinolone-resistant C. difficile.
Pawlowski SW; Archbald-Pannone L; Carman RJ; Alcantara-Warren C; Lyerly D; Genheimer CW; Gerding DN; Guerrant RL
J Hosp Infect; 2009 Oct; 73(2):185-7. PubMed ID: 19709778
[No Abstract] [Full Text] [Related]
19. Moxifloxacin and biofilm production by coagulase-negative staphylococci.
Pérez-Giraldo C; Gonzalez-Velasco C; Sánchez-Silos RM; Hurtado C; Blanco MT; Gómez-García AC
Chemotherapy; 2004 Jun; 50(2):101-4. PubMed ID: 15211086
[TBL] [Abstract][Full Text] [Related]
20. In vitro antimicrobial activity of moxifloxacin against bacterial strains isolated from blood of neutropenic cancer patients.
Cometta A; Marchetti O; Calandra T; Bille J; Kern WV; Zinner S;
Eur J Clin Microbiol Infect Dis; 2006 Aug; 25(8):537-40. PubMed ID: 16896825
[No Abstract] [Full Text] [Related]
[Next] [New Search]
